Clinical trials: acne
Acne Vulgaris
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
- Trial name
- NCT03573518
- Testing
- BTX 1503, Vehicle
- Where
- 36 sites in United States, Australia
- Volunteers
- 368 people
- Sponsor
- Botanix Pharmaceuticals
Acne
Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne
Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group comparison study in subjects with severe acne vulgaris on the face.
- Trial name
- POWER (NCT01474590)
- Testing
- Epiduo/Tactuo, vehicle gel, doxycycline 200mg
- Where
- 25 sites in Canada
- Volunteers
- 266 people
- Sponsor
- Galderma R&D
Acne Scars - Mixed Atrophic and Hypertrophic
Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
- Trial name
- NCT05358860
- Testing
- Sofwave
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sofwave Medical LTD
Acne Vulgaris
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
This is a 12-week, multi-center, double-blind, randomized, three-arm, vehicle-controlled study. Subjects will be randomized (1:1:1) to 1% or 2 % BPX-01 gel, or vehicle.
- Trial name
- OPAL (NCT02815332)
- Testing
- BPX-01 1% Minocycline Topical Gel, BPX-01 2% Minocycline Topical Gel, BPX-01 Vehicle Topical Gel
- Where
- 15 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioPharmX, Inc.
Acne Vulgaris
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
The primary objective of this study is to compare the efficacy, safety and tolerability of IDP-121 Lotion and vehicle in the treatment of subjects with acne vulgaris.
- Trial name
- NCT02535871
- Testing
- IDP-121 Lotion, IDP-121 Vehicle Lotion
- Volunteers
- 800 people
- Sponsor
- Valeant Pharmaceuticals
Acne Vulgaris
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12…
- Trial name
- NCT02073448
- Testing
- GK530G, CD0271, CD1579
- Where
- 13 sites in Japan
- Volunteers
- 417 people
- Sponsor
- Galderma R&D
Polycystic Ovary Syndrome (PCOS)
MLE4901 vs. Placebo for the Treatment of PCOS
This is a Phase 2b double-blind, randomized, parallel-group, placebo-controlled study of MLE4901 versus placebo in women with PCOS.
- Trial name
- NCT02865915
- Testing
- MLE4901
- Where
- 31 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millendo Therapeutics US, Inc.
Acne Vulgaris
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1%…
- Trial name
- NCT02709096
- Testing
- BPX-01, 1% Topical Gel, BPX-01 Vehicle Gel
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- BioPharmX, Inc.
Acne Vulgaris
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
- Trial name
- NCT00666900
- Testing
- Low Strength IDP-107, High Strength IDP-107
- Where
- 25 sites in United States
- Volunteers
- 366 people
- Sponsor
- Dow Pharmaceutical Sciences
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week…
- Trial name
- STOP-HS2 (NCT05620836)
- Testing
- Povorcitinib
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 619 people
- Sponsor
- Incyte Corporation
Acne Vulgaris
Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
- Trial name
- NCT02218034
- Testing
- AGN-190168 Formulation 1, AGN-190168 Formulation 2, tazarotene gel 0.1%
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Allergan
Acne Vulgaris
Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.
A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.
- Trial name
- NCT00714714
- Testing
- Adapalene Gel, Tretinoin Gel
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris
Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75% gel. This study is designed to evaluate the safety and efficacy of this formulation in subjects with Acne Vulgaris
- Trial name
- NCT02616614
- Testing
- Onexton, Clindamycin/benzoyl peroxide gel
- Where
- 17 sites in United States
- Volunteers
- 862 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Acne Vulgaris, Acne
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
Acne vulgaris, or acne, is one of the most prevalent diseases worldwide, with skin conditions being one of the top causes of years lived with disability and non-fatal disease burden.
- Trial name
- OREA (NCT05131373)
- Testing
- ORG101 - Experimental 1
- Where
- 6 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acne Vulgaris
A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers
This study will assess the potential of tazarotene foam to cause sensitization during a 48 hour challenge following 21 days of exposure on the skin of healthy volunteers.
- Trial name
- NCT01114841
- Testing
- Tazarotene Foam, Vehicle Foam
- Where
- United States
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris
Safety and Efficacy of IDP-123 Lotion (0.045% tazarotene) to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris
- Trial name
- NCT02938494
- Testing
- IDP-123 Lotion, Tazorac Cream, Vehicle Lotion
- Where
- 16 sites in United States
- Volunteers
- 210 people
- Sponsor
- Bausch Health Americas, Inc.
Acne, Scars
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.
The scope of this open label clinical trial is to evaluate and confirm the performance of Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild to moderate acne.
- Trial name
- NCT04806594
- Testing
- Papix acne scar
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Relife S.r.l.
Acne Vulgaris
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
- Trial name
- NCT02815280
- Testing
- FMX-101, 4% minocycline foam, Vehicle Foam
- Where
- 36 sites in United States, Dominican Republic
- Volunteers
- 495 people
- Sponsor
- Vyne Therapeutics Inc.
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT06799000
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals